Savara (NASDAQ:SVRA) Sees Unusually-High Trading Volume – Still a Buy?

Savara Inc. (NASDAQ:SVRA) shares saw an uptick in trading volume on Friday . 1,314,910 shares traded hands during mid-day trading, a decline of 8% from the previous session’s volume of 1,435,789 shares.The stock last traded at $6.4250 and had previously closed at $6.37.

Wall Street Analyst Weigh In

SVRA has been the topic of several analyst reports. HC Wainwright increased their price target on Savara from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. Citigroup reaffirmed an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Wells Fargo & Company began coverage on Savara in a research report on Monday, October 20th. They issued an “overweight” rating and a $7.00 price objective on the stock. Finally, Guggenheim lifted their target price on shares of Savara from $8.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.29.

Savara Price Performance

The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. The stock’s 50-day moving average price is $4.28 and its 200 day moving average price is $3.27. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -12.14 and a beta of 0.23.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Equities research analysts expect that Savara Inc. will post -0.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

A number of hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after purchasing an additional 9,463 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of Savara during the 3rd quarter valued at approximately $44,000. Prudential Financial Inc. acquired a new position in Savara in the second quarter valued at approximately $30,000. BNP Paribas Financial Markets grew its position in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after acquiring an additional 4,626 shares during the period. Finally, May Hill Capital LLC purchased a new position in Savara in the second quarter worth approximately $32,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.